

# New insights in osteoporosis management within the Fracture Liaison Service (FLS)

Piet Geusens, MD, PhD

Prof. *Em.* Rheumatology

UMaastricht en UHasselt


# Disclosures

- Grants from Sandoz, Celltrion, Fresenius, MSD, Amgen, Galapagos, Viatrix
- None in the context of this presentation

- Fracture Liaison Service (FLS)
  - Post-Fracture Care (PFC)
  - Secondary fragility fracture prevention services (SFFPS)
- Orthogeriatric Care (OGC) after hip fracture

# The burden of clinical fractures in 50+ subjects worldwide

Global Burden of Disease Study (GBD) 2019



33% fracture incidence increase from 1990 to 2019

Wu, Lancet Healthy Longev, 2021

# The burden of clinical fractures in 50+ subjects in the EU

Estimated total fracture incidence in EU+2 in 2019

Fracture site	Women	Men	Women and men
Hip fractures	603,967	222,741	826,708
Vertebral fractures	432,479	230,064	662,544
Forearm fractures	528,109	108,596	636,705
Other fractures *	1,293,964	855,626	2,149,591
All fractures	2,858,519	1,417,028	4,275,547

\*humerus, ribs, tibia, pelvis and other femoral fractures

Estimated\*\* annual number of fragility fractures\*\*\* /1000 of the population of 50+ subjects in EU+2 in 2019

Mean:  $20/1000 = 1/50$  per year

Range: 14/1000 (Romania) to 38/1000 (Slovakia)

\*\*when not available, based on nearest country or Swedish relationship between hip and other fractures

\*\*\*hip, clinical vertebral, forearm, humerus, ribs, tibia, pelvis, other femoral fracture

The 50+ patients with  
a recent clinical fracture


What are their perspectives?

# Long-term risk of any recurrent clinical fracture

Study	<i>n</i>	Relative Risk (RR)	FU (yrs)	Fractures	
Klotzbuecher (2000)		2.2 (women and men, all ages)	1-11	any clinical	
Kanis (2004)	60,000	1.9 (women and men, age 21-106 yrs)	up to 20	any clinical	
Center (2007)	4,000	2.0 (60+ women), 3.5 (60+ men)	16	clinical low-trauma	
Van Geel (2008)	4,100	2.1 (postmenopausal women)	20	any clinical	
Kanis (2023)	2.1MM	1.9 (women~men, age 20-116 yrs)	~9	any clinical	Excluded: skull, face, hands, feet, ankle, and patella and tibial and fibular fractures in men

These data and analyses suggest that subsequent fracture risk is constant over time

No data on time between first and subsequent fracture





*Klotzbuecher, JBMR, 2000*  
*Kanis, Bone, 2004*  
*Center, JAMA, 2007*  
*van Geel, ARD, 2008*  
*Kanis, OI, 2023*

# Clinical fractures cluster in time: the *imminent* subsequent fracture risk

**A window of opportunity for early evaluation  
and treatment decisions for secondary fracture prevention**

Recurrence of major osteoporotic fractures in women and men  
(age 33-88 yrs, n=18,872)



Kanis, OI, 2018



# Risk of any subsequent fracture per site of recent ( $\leq 2$ yr) fracture

Nation-wide retrospective cohort study in Sweden

3,423,320 women and men >50 years

>450,000 had a first fracture:

70,254 with a recent MOF ( $\leq 2$  yrs)


75,526 with a recent non-MOF ( $\leq 2$  yrs)

293,051 with an old fracture (>2 yrs)


>145,000 with subsequent fracture  
within 2 years

The authors suggested that all patients with a recent clinical fracture should be included in secondary prevention programs such as the FLS

\*HR were somewhat lower but remained significant after including competing risk for mortality



# From relative risk to absolute imminent subsequent fracture risk




~280,000 women, 95%  $\geq 65$  yrs  
Accounting for competing risk of mortality

# Considerations for the FLS


- 1/ Any clinical fracture is a signal for imminent and long-term subsequent fracture risk
- 2/ Disturbed microarchitecture is a risk factor for fractures beyond aBMD
- 3/ A full fracture history at the FLS includes imaging of the thoracic and lumbar spine
- 4/ Patients with a recent clinical fracture have frequently associated diseases and extra-skeletal risk factors
- 5/ Implementation of the FLS and its effects on subsequent fractures, mortality and falls

# Excess mortality after a recent clinical fracture

1-year




Long-term



Largest proportion of mortality:  
pneumonia, besides dehydration, urinary tract infection and sepsis

# Cumulative incidences of recurrent low-trauma fractures taking into account the competing risk of mortality

*Example in 60+ Women (n=952)*



Community-dwelling participants aged 60+ years  
from Dubbo Osteoporosis Epidemiology Study, Australia

*Bliuc, JBMR, 2013*

# Considerations for the FLS

- 1/ Any clinical fracture is a signal for imminent and long-term subsequent fracture risk, except when life expectancy is short
- 2/ Disturbed microarchitecture is a risk factor for fractures beyond aBMD
- 3/ A full fracture history at the FLS includes imaging of the thoracic and lumbar spine
- 4/ Patients with a recent clinical fracture have frequently associated diseases and extra-skeletal risk factors
- 5/ Implementation of the FLS and its effects on subsequent fractures, mortality and falls

# Other imminent changes after a recent fracture


Decrease in aBMD, physical performance, quality of life (QoL), increase of fear of falling

## Risk of falls:


After clinical fracture: 15% within 3 months (n=277, mean age: 72 yrs)

After hip fracture: 56% within 1 year, one fall: 28%, recurrent falls: 28% (n=193, mean age: 81 yrs)

After FLS visit within 1 year  
(n=974, W+M, mean age: 76 yrs)




After FLS visit within 1-3 years  
(n=488, W+M, mean age: 65 years)



## Publications on post-fracture care

Osteoporos Int (2003) 14: 1028–1034  
DOI 10.1007/s00198-003-1507-z






# Publications

Care for patients with a recent clinical fracture

International guidelines




Marsh, OI, 2011; Eisman, JBMR, 2012; Blain, Aging, 2016; Lems, ARD, 2017; Dreinhofer, Injury, 2018; Akesson, OI, 2022


The 50+ patients with  
a recent clinical fracture

What are their characteristics?

# Risk estimation algorithms for calculating fracture risk




# Risk factors in patients with a recent fracture (*n=568, women and men, mean age: 67 yrs*)




van Helden, JBJS, 2008

# Clinical bone- and fall-related comorbidities and medications at the FLS ( $n=1282$ ) based on medical history



# The fracture in a wider and deeper context





# Long-term risk of any recurrent clinical fracture

Study	N	Relative Risk (RR)	
Kanis 2023	2.1MM	1.9 (95% CI: 1.7-2.1), women~men	64 prospective cohorts

Outcome fracture	Number of cohorts	Unadjusted		Adjusted for BMD		Gradient of risk (HR/SD) for BMD	Proportion of risk (%) from BMD
		HR	95% CI	HR	(95% CI)		
Any	52	1.79	1.67–1.92	1.65	1.53–1.78	1.45	14

proportion of risk from aBMD: 14%


# FRAX 10-year risk phenotypes



- Fracture risk assessment tools such as FRAX provide a readily available approach for stratifying the population to assess the subsequent fracture risk
  - but is largely beyond aBMD for FRAX
- FRAX cannot provide interpretation into the mechanisms leading to bone fragility



# Fracture incidence and association with aBMD in 55+ men and women: the Rotterdam Study (*n*=7806, 7 years follow up)




Most patients with  
a non-vertebral fracture  
do not have  
an osteoporotic phenotype  
based on aBMD

# aBMD (areal BMD): Diagnostic versus treatment thresholds

- aBMD has a high specificity to predict fractures
  - the osteoporotic phenotype (T-score  $\leq -2.5$ ) has a high risk of fractures
- aBMD has a low sensitivity
  - most patients who fracture do not have an osteoporotic phenotype
- This raises the questions:
  - What is the role of other bone-related risks than aBMD?
  - What is the role of extra-skeletal risks?


*Siris, JAMA, 2001  
Kanis, Lancet, 2002  
Kanis, Bone, 2002  
Schuit, Bone, 2004  
Kanis, OI, 2023  
Mai, JCEM, 2019*

## Determinants of fracture



Bone evaluation at the FLS:  
more than assessment with DXA-aBMD







# Bone width, micro-architecture and aBMD



Jepsen, JBMR, 2017  
Bigelow, JBMR, 2019  
Bolger, J Struct Biol, 2020

# High-resolution peripheral quantitative CT scan (HR-pQCT): measuring microarchitecture *in vivo*


(Xtreme CT1+2 devices, Scanco, Switzerland)




Boutroy, JCEM, 2005  
Whittier, OI, 2020  
Whittier, Bone, 2021  
van den Bergh, OI, 2021

# Bone micro-architecture parameters by HR-pQCT are related to risk of clinical fractures, independent of aBMD


Single cortical and trabecular parameters and micro-finit element analysis ( $n=7254$ )



Hypothesis driven analysis:  
Composite of decreased trabecular density and increased cortical porosity predicts imminent fracture risk  
**better than aBMD and FRAX ( $n=1539$ )**



+






# AI-driven analysis

## Bone Microarchitecture Phenotypes Identified in Older Adults ( $n=5873$ )


**Healthy phenotype**  
(male, 49 years)

---

**b**



**c**



<b>Size</b>	normal
<b>Cortex</b>	thick
<b>Trabeculae</b>	well-connected



# AI-driven analysis

## Bone Microarchitecture Phenotypes Identified in Older Adults ( $n=5873$ )



**Healthy phenotype**  
(male, 49 years)

**Low density phenotype**  
(female 75 years)

**b**



**c**



**Size**

normal

**Cortex**

thick

**Trabeculae**

well-connected

normal

thinning

degradation



# AI-driven analysis


## Bone Microarchitecture Phenotypes Identified in Older Adults ( $n=5873$ )

**Healthy phenotype**  
(male, 49 years)


**Low density phenotype**  
(female 75 years)

**Low volume phenotype**  
(female, 79 years)

**b**



**c**



**Size** normal  
**Cortex** thick  
**Trabeculae** well-connected

normal  
thinning  
degradation

smaller  
thick and dense  
deficits



# AI-driven analysis

## Bone Microarchitecture Phenotypes Identified in Older Adults ( $n=5873$ )

**Healthy phenotype**  
(male, 49 years)

**Low density phenotype**  
(female 75 years)


**Low volume phenotype**  
(female, 79 years)



**Size** normal  
**Cortex** thick  
**Trabeculae** well-connected

normal  
thinning  
degradation

smaller  
thick and dense  
deficits




# Considerations for the FLS

- 1/ Any clinical fracture is a signal for imminent and long-term subsequent fracture risk, except when life expectancy is short
- 2/ Disturbed microarchitecture is a risk factor for fractures beyond aBMD**
- 3/ A full fracture history at the FLS includes imaging of the thoracic and lumbar spine
- 4/ Patients with a recent clinical fracture have frequently associated diseases and extra-skeletal risk factors
- 5/ Implementation of the FLS and its effects on subsequent fractures, mortality and falls




# Vertebral fractures (VFs) are a reflection of bone microarchitecture independent of aBMD

- VFs are predictors of VF and non-VF
- Microarchitecture is more disturbed:
  - In subjects with a VF than with a non-VF
  - In postmenopausal women with a recent non-VF with a VF than without a VF




*Ross, Ann Intern Med. 1991*  
*McCloskey, JBMR, 2008*  
*Chen, JBMR, 2009*  
*Stein, JCEM, 2012*  
*Vranksen, OI, 2019*

# Prevalence of vertebral fractures (VF) in patients with a non-VF at the FLS




Genant, *OI*, 2003; Gallagher, *OI*, 2007; Howat, *Clin Endo*, 2007; Roux, *Rheum*, 2011; van de Velde, *OI*, 2017; Malgo, *OI*, 2017; Ginther, *End Pract*, 2017; Reniu, *Arch Osteop*, 2017; Schousboe, *JBMR*, 2019; Schousboe, *Bone*, 2019; Aboudiab, *OI*, 2020; Lems, *OI*, 2021

% of patients with a non-VF at the FLS, and having at least one vertebral fracture before and after implementation of VFA



# Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services

W. F. Lems<sup>1</sup>  • J. Paccou<sup>2</sup> • J. Zhang<sup>3</sup> • N. R. Fuggle<sup>3</sup> • M. Chandran<sup>4</sup> • N. C. Harvey<sup>3</sup> • C. Cooper<sup>3,5</sup> • K. Javaid<sup>5</sup> • S. Ferrari<sup>6</sup> • K. E. Akesson<sup>7</sup> • International Osteoporosis Foundation Fracture Working Group


- DXA-VFA should be performed in all patients visiting a FLS
  - 2/3 of vertebral fractures are subclinical
  - they reflect the presence of more severe microarchitectural deterioration
  - prevalent vertebral fractures may modify risk category and therapy
  - allows diagnosing incident new vertebral fractures for optimal treatment monitoring

# Considerations for the FLS

- 1/ Any clinical fracture is a signal for imminent and long-term subsequent fracture risk, except when life expectancy is short
- 2/ Disturbed microarchitecture is a risk factor for fractures beyond aBMD
- 3/ A full fracture history at the FLS includes imaging of the thoracic and lumbar spine**
- 4/ Patients with a recent clinical fracture have frequently associated diseases and extra-skeletal risk factors
- 5/ Implementation of the FLS and its effects on subsequent fractures, mortality and falls



## Determinants of fracture



The fracture patient at the FLS  
needs more than assessment of bone

# Prevalence of known and newly diagnosed metabolic bone diseases (after clinical and a limited laboratory examination)

*Endocrine Reviews*, 2022, Vol. 43, No. 2, 240–313

<https://doi.org/10.1210/endrev/bnab028>

Review



---

Review

## Secondary Osteoporosis

Peter R. Ebeling,<sup>1,2</sup> Hanh H. Nguyen,<sup>1,2,3</sup> Jasna Aleksova,<sup>2,4</sup>  
Amanda J. Vincent,<sup>2,5</sup> Phillip Wong,<sup>1,2,4</sup> and Frances Milat<sup>1,2,4</sup>

873. Rolfes MC, Deyle DR, King KS, Hand JL, Graff AH, Derauf C.  
Fracture incidence in Ehlers-Danlos syndrome - a population-  
based case-control study. *Child Abuse Negl.* 2019;**91**:95-101.


# Multimorbidity clusters and mortality risk at the time of fracture

Nationwide cohort study in 307,870 adults older than 50 years (mean: 75 yrs) with a recent low-trauma fracture in Denmark

Women ( $n=212,498$ ):

History of stroke:	7.3%
History of MI:	6.4%

## Risk factors for 1-year imminent non-vertebral fracture (SOF study, women $\geq 65$ years old)



\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$

Barron, Ol, 2020

# Considerations for the FLS

- 1/ Any clinical fracture is a signal for imminent and long-term subsequent fracture risk, except when life expectancy is short
- 2/ Disturbed microarchitecture is a risk factor for fractures beyond aBMD
- 3/ A full fracture history at the FLS includes imaging of the thoracic and lumbar spine
- 4/ Patients with a recent clinical fracture have frequently associated diseases, comorbidities and extra-skeletal risk factors and these are related to imminent subsequent fracture risk
- 5/ Implementation of the FLS and its effects on subsequent fractures, mortality and falls

# How to implement a Fracture Liaison Service (FLS)?

# Secondary fracture prevention at the FLS:

## a 5-step plan in the Netherlands

and 11 key performance indicators (KPI) of the IOF/FFN/NOF

### 1/ Identification

KPI 1: Individuals with Non-Spine fractures

KPI 2: Individuals with Spine fractures

Orthopaedic fracture care  
Orthogeriatric care after hip fracture



### 2/ Risk assessment (DXA+VFA) Fall risk

Fracture Liaison Service

12 weeks

KPI 3: Fracture risk assessment  
KPI 4: DXA scan  
KPI 5: Falls risk assessment  
KPI 6: AOM recommendation

### 3/ Investigation (+lab before treatment)

16 weeks

52 weeks

### 4/ Treatment initiation (anabolics when low BMD+VF) Fall prevention in fallers

KPI 7: Follow-up  
KPI 8: AOM initiation  
KPI 9: Strength and balance initiation

### 5/ Follow-up (+GP)

KPI 10: AOM persistence

Adherence  
Fall risk  
Subsequent fracture risk  
QoL  
Mortality risk

KPI 11: Data completeness





# The Capture the Fracture® Partnership: an overview of a global initiative to increase the secondary fracture prevention care for patient benefit

M. K. Javaid<sup>1</sup> · R. Pinedo-Villanueva<sup>2</sup> · A. Shah<sup>2</sup> · Z. Mohsin<sup>2</sup> · M. Hiligsmann<sup>3</sup> · A. Motek-Soulié<sup>4</sup> · N. R. Fuggle<sup>5</sup> · P. Halbout<sup>4</sup> · C. Cooper<sup>2,5</sup>

## Resource Center

A comprehensive collection of free resources to support those who want to implement, improve, or advocate for Post-Fracture Care Coordination Programs (PFC) / Fracture Liaison Services (FLS).

[Click below to find your resources](#)



YOU WANT TO  
IMPLEMENT A PFC  
PROGRAM/FLS

- MENTORSHIP
  - ☐ Mentorship programme overview
  - ☐ Mentorship onsite training
  - ☐ Mentorship resources

BENCHMARKING AND AUDIT

TRAINING FOR HCPS

FRACTURE BURDEN

PATIENT RESOURCES

TOOLS



YOU ALREADY  
HAVE A PFC  
PROGRAM/FLS

BENCHMARKING AND AUDIT

TRAINING FOR HCPS

MENTORSHIP

PATIENT RESOURCES

TOOLS



ADVOCATING  
FOR PFC  
PROGRAMS/FLS

POLICY TOOLKITS

AUDIT REPORTS

IOF TOUR

GLOBAL PATIENT CHARTER

CTF MAP OF BEST PRACTICE



# Effects of implementation of the bone- and fall-related phenotypes at the FLS

- FLS increases:
  - clinical, DXA+VFA, laboratory and fall risk evaluation
  - diagnosis and treatment of underlying diseases
  - adequate calcium, vitamin D and protein intake
  - treatment initiation based on further specification of very high risk after a recent fracture, taking into account the additional risk factors according to the patient's phenotype
  - persistence of treatment
- FLS care is associated with a significantly lower imminent 2-year probability of:
  - subsequent fractures: -30% (CI: -7% to -48%)
  - mortality (in pre/post FLS studies): -35% (CI: -5% to -56%)
- The quality assessment revealed some important methodological issues


*Javaid, OI, 2020*

*Li, OI, 2021*

*Pinedo-Villanueva, JBMR, 2023*

*Silva, Arch Osteop, 2023*



# Expected Benefits and Budget Impact From a Microsimulation Model Support the Prioritization and Implementation of FLSs



FLSs was highly cost-effective at £8258 per QALY gained over the first 5 years.

# Cost-effectiveness analysis of fracture liaison services: a Markov model using Dutch real-world data

- For patients with a recent fracture aged 50 years and older, the presence of an FLS was associated with
  - a lifetime €45 higher cost
  - 0.11 additional QALY gained
  - leading to an ICER of €409 per QALY gained
  - indicating FLS was cost-effective compared to no-FLS at the Dutch threshold of €20,000/QALY
- The FLS remained cost-effective across different age categories
- The higher the treatment initiation rate in FLS, the greater the cost-effectiveness of FLS



# Risk factors for non-attendance at the FLS ( $N=2006$ )

40% of invited patients did not attend the FLS

## → Demographic factors contributing to be a non-attender

	Odds Ratio	
Male	1.67 (1.17; 2.42)	.002
Living alone	1.98 (1.43; 2.74)	<.001
Age > 70 yr.	1.87 (1.35; 2.60)	<.001
Low income	3.03 (2.00; 4.55)	<.001
Low education	3.03 (2.00; 4.55)	<.001

## → Extrinsic Motivations contributing to be a non-attender

No advice was perceived to have a DXA and to visit the FLS	9.1 (6.7; 12.5)	<.001
--	-----------------	-------

Role for  
health care  
professionals

## → Intrinsic Motivations contributing to be a non-attender

I am not interested in my bone strength*	2.08 (1.50; 2.94)	<.001
I do not think that my fracture risk is increased after sustaining this fracture**	1.72 (1.08; 2.86)	.024

## → Frailty: Tilburg Frailty Indicator (TFI)

Frailty	2.12 (1.51; 2.98)	.002
---------	-------------------	------

# Initiatives for implementation of the FLS



## Patients' preferences for fracture risk communication: the Risk Communication in Osteoporosis (RICO) study

Charlotte Beaudart<sup>1,2,3</sup> · Mitali Sharma<sup>4</sup> · Patricia Clark<sup>5</sup> · Saeko Fujiwara<sup>6</sup> · Jonathan D. Adachi<sup>7</sup> · Osvaldo D. Messina<sup>8,9</sup> · Suzanne N. Morin<sup>10</sup> · Lynn A. Kohlmeier<sup>11</sup> · Caroline B. Sangan<sup>12</sup> · Xavier Nogues<sup>13</sup> · Griselda Adriana Cruz-Priego<sup>14</sup> · Andrea Cavallo<sup>8</sup> · Fiona Cooper<sup>12</sup> · Jamie Grier<sup>12</sup> · Carolyn Leckie<sup>7</sup> · Diana Montiel-Ojeda<sup>14</sup> · Alexandra Papaioannou<sup>7</sup> · Nele Raskin<sup>1</sup> · Leonardo Yurquina<sup>15</sup> · Michelle Wall<sup>16</sup> · Olivier Bruyère<sup>2</sup> · Annelies Boonen<sup>1,17</sup> · Elaine Dennison<sup>18</sup> · Nicholas C. Harvey<sup>18,19</sup> · John A. Kanis<sup>20,21</sup> · Jean-François Kaux<sup>22</sup> · E. Michael Lewiecki<sup>23</sup> · Oscar Lopez-Borbon<sup>3</sup> · Zoé Paskins<sup>24,25</sup> · Jean-Yves Reginster<sup>2</sup> · Stuart Silverman<sup>3,26</sup> · Mickaël Hiligsmann<sup>1</sup>

332 subjects in 9 countries, 48% history of fracture

Understand traffic light  
Convincing treatment initiation

61% (range: 7-80%)  
61% (range: 13-97%)

After a recent clinical fracture FRAX needs adjustment  
for recency of falls and fractures and number of previous fractures


### PRESENTATION N°1

This first way to explain your fracture risk is verbal or in writing

Your risk of major osteoporosis-related fracture (e.g. hip, spine, wrist fracture)  
is 21% over 10 years


### PRESENTATION N°2

The presentation is supplemented with a visual presentation of the risk using a coloured graph



### PRESENTATION N°3

The presentation is supplemented with a visual presentation of the risk using icon array





# The role of non-physician health professionals

## EULAR initiatives

Osteoporosis

**RMD  
Open**







Rheumatic &  
Musculoskeletal  
Diseases

ORIGINAL RESEARCH

### Prevention and management of osteoporotic fractures by non-physician health professionals: a systematic literature review to inform EULAR points to consider

Nicky Wilson <sup>1</sup>, Emalie Hurkmans,<sup>2</sup> Jo Adams <sup>1</sup>, Margot Bakkers,<sup>3</sup> Petra Balážová,<sup>4,5</sup> Mark Baxter,<sup>6</sup> Anne-Birgitte Blavnsfeldt,<sup>7</sup> Karine Briot <sup>8</sup>, Catharina Chiari,<sup>9</sup> Cyrus Cooper,<sup>10</sup> Razvan Dragoi,<sup>10</sup> Gabriele Gäbler,<sup>9</sup> Willem Lems,<sup>11</sup> Erika Mosor,<sup>12</sup> Sandra Pais,<sup>13</sup> Cornelia Simon,<sup>10</sup> Paul Studenic,<sup>14</sup> Simon Tilley,<sup>15</sup> Jenny de la Torre,<sup>16</sup> Tania A Stamm <sup>17</sup>

### 2019 EULAR points to consider for non-physician health professionals to prevent and manage fragility fractures in adults 50 years or older


Jo Adams <sup>1</sup>, Nicky Wilson <sup>1</sup>, Emalie Hurkmans,<sup>2</sup> Margot Bakkers,<sup>3</sup> Petra Balážová,<sup>4,5</sup> Mark Baxter,<sup>6</sup> Anne-Birgitte Blavnsfeldt,<sup>7</sup> Karine Briot <sup>8</sup>, Catharina Chiari,<sup>9</sup> Cyrus Cooper,<sup>10</sup> Razvan Gabriel Dragoi,<sup>11</sup> Gabriele Gäbler,<sup>12</sup> Willem Lems,<sup>13</sup> Erika Mosor,<sup>12</sup> Sandra Pais,<sup>14</sup> Cornelia Simon,<sup>15</sup> Paul Studenic <sup>16</sup>, Simon Tilley,<sup>6,17</sup> Jenny de la Torre-Aboki <sup>18</sup>, Tania A Stamm <sup>12,19</sup>

Aim is to involve non-physician health professionals in all steps of primary and secondary fracture prevention, including at the FLS

*Wilson, RMD Open, 2020  
Adams, ARD, 2021*

CONSENSUS STATEMENT

## Establishing consensus recommendations for long-term osteoporosis care for patients who have attended an Australian fracture liaison service: a Delphi study

Michael J. Bennett<sup>1,2,3,4</sup>  · Jacqueline R. Center<sup>4,5</sup> · Lin Perry<sup>6,7</sup>

Clear consensus among experts in many key areas of FLS integration with primary care.


While experts agreed that primary care is the most appropriate setting for long-term osteoporosis care, overall confidence in primary care systems to achieve this was low.

The role of (and responsibility for) adherence monitoring in a resource-limited setting remains to be defined.




# Drug treatment considerations

In high-risk patients



In very high-risk patients



# Pivotal RCTs on fracture prevention *(since 2003)*

## *low BMD, prevalent VF and/or recent fracture*

### Versus placebo:

				Inclusion criteria		
				<u>Low BMD</u>	<u>Vertebral fracture</u>	<u>Other</u>
Alendronate	Black	1996	Lancet		≥1	
	Cummings	1998	JAMA	Low BMD		
Risedronate Reginster	2000	OI			>1	
	Harris	1999	JAMA		≥1	
	McClung	2001	NEJM			low BMD + clinical risks
Raloxifene	Siris	2002	OI	low BMD	and/or prevalent VF	
Zoledronate	Lyles	2007	NEJM			recent hip fracture
Denosumab	Cummings	2009	NEJM	low BMD		
Teriparatide	Neer	2001	NEJM		>1 (or <2 + low BMD)	
Romosozumab	McClung	2014	NEJM	low BMD		

### Superiority above risedronate:

Teriparatide	Kendler	2017	Lancet	low BMD	+	VF
	Geusens	2018	JBMR	low BMD	+	recent VF

### Superiority above alendronate:

Romosozumab	Saag	2017	NEJM	low BMD	+	VF	or recent hip fracture
-------------	------	------	------	---------	---	----	------------------------

Subsequent fractures within 3 years in patients attending the FLS (*n*=488)  
after extensive examination of the phenotype and treatment according to Dutch guidelines  
according to prevalent VFs at baseline

53 patients with 60 fractures

Baseline moderate or severe VF: 14%


Cumulative incident fractures  
within 3 years after FLS visit:

After moderate to severe VF: 24%

After no or mild VF: 9%

Table 2 Predictors of refracture: results of the Cox's proportional hazard model			
Predictor	Unit of comparison	HR and 95% CI	P value
Gender	Women vs men	1.39 (0.68 to 2.83)	0.362
Age	+5 years	0.97 (0.82 to 1.13)	0.662
Index fracture	Major or hip vs all other	0.68 (0.35 to 1.33)	0.263
BMD	−0.12 g/cm <sup>2</sup>	1.30 (0.95 to 1.78)	0.101
Prevalent vertebral fracture	Yes vs no	3.88 (2.07 to 7.27)	<0.0001

# Incidence of falls after FLS (n=488)




959 falls (weekly diary)  
 40% had one fall  
 5% of falls resulted in a fracture  
 78% of fractures were fall-related  
 (half of them after a first fall)

# Incidence of fractures (in 53 patients with 60 fractures) after FLS visit (n=488)



**Table 2** Predictors of refracture: results of the Cox's proportional hazard model

Predictor	Unit of comparison	HR and 95% CI	P value
Gender	Women vs men	1.39 (0.68 to 2.83)	0.362
Age	+5 years	0.97 (0.82 to 1.13)	0.662
Index fracture	Major or hip vs all other	0.68 (0.35 to 1.33)	0.263
BMD	-0.12 g/cm <sup>2</sup>	1.30 (0.95 to 1.78)	0.101
Prevalent vertebral fracture	Yes vs no	3.88 (2.07 to 7.27)	<0.0001
Fall	Yes vs no	8.58 (3.09 to 23.8)	<0.0001


# Incident falls and subsequent fractures in patients attending the FLS after extensive examination of the phenotype and treatment according to Dutch guidelines



# Physical capacity and activity in women after recent clinical fracture at the FLS (*mean age: 65 yrs, n=~400*)




- (I) hip fractures
- (II) major fractures; vertebra, multiple rib, humerus, pelvis, distal femur and proximal tibia,
- (III) minor fractures: all other fractures (including finger and toe fractures).




# Antiresorptive medication may enhance exercise efficacy on BMD at the proximal femur and lumbar spine (exploratory analyses)

High-intensity resistance and impact training (HiRiT) versus HiRiT + medication



Low-intensity exercise (Buff Bones® [BB]) versus BB + medication



HiRiT HiRiT-med BB BB-med

Chotiyarnwong, JBMR, 2020  
Kistler-Fischbacher, JBMR, 2021




# Knowledge gaps at the FLS and research agenda

- Fracture risk evaluation
  - Need for refined imminent fracture risk prediction algorithms
  - Need for better prediction of fall risk
  - Role of new evaluation techniques (QCT and other imaging techniques)
- Need for long-term observational studies with adequate methodology
  - Studies about the intensity and sequence of drug treatment after a recent fracture
  - Fall prevention and exercise combined with drug treatment
- Patient preferences and how to approach and treat non-attenders

# Considerations for the FLS

- 1/ Any clinical fracture is a signal for imminent and long-term subsequent fracture risk
- 2/ Disturbed microarchitecture is a risk factor for fractures beyond aBMD
- 3/ A full fracture history at the FLS includes imaging of the thoracic and lumbar spine
- 4/ Patients with a recent clinical fracture have frequently associated diseases and extra-skeletal risk factors
- 5/ Implementation of the FLS and its effects on subsequent fractures, mortality and falls

## Bone Staff



## Visiting Professors



## Scientific advices



## Heads of department



KULeuven




UMaastricht



UHasselt

## PhD's



## PhD candidates







Thank you



*Stichting De Weijerhorst*

